Tuning Up Part D Amid Drug Pricing Debate; MedPAC Likely To Urge More Flexibility For Plans Setting Formularies
This article was originally published in RPM Report
Executive Summary
The Medicare Payment Advisory Committee (MedPAC) will be moving forward with specific recommendations to improve prescription drug provisions under Part D and Part B – but is not ready to take the lead on policy development addressing prescription drug prices overall.